Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
Nicole Wright @UofAlabama highlights lack of centralised #fracture database. Aggregating data showed 2.8% of 95 mil admissions were fracture related but also a lot of emergency room attendance for humerus fractures. Why do hip fracture rates go up but spi
— UCB News (@ucb_news) 22.09.2019 -
Nicole Wright @UofAlabama explains the great aims of the US bone and joint initiative and how the 4th edition shows the high rates of #osteoporosis in different racial groups #ASBMR2019 #UCBtakeover
— UCB News (@ucb_news) 22.09.2019 -
After last year’s report published by @iofbonehealth around the impact of #osteoporosis and #fragilityfractures in the EU6, it’s worrying to see a similar impact in the US #ASBMR2019 #UCBtakeover
— UCB News (@ucb_news) 22.09.2019
